TC BioPharm PLC a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, is proud to announce its participation at the upcoming Sequire Investor Summit.
EDINBURGH, Scotland, April 19, 2023 (GLOBE NEWSWIRE) -- TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, is proud to announce its participation at the upcoming Sequire Investor Summit. This highly anticipated event, scheduled for April 24-26, 2023 at La Concha Resort in San Juan, Puerto Rico, promises to offer an array of exciting opportunities for funds, companies, and investors.
One of the standout highlights of this year’s summit is the focus on great tax laws in Puerto Rico, which offers a unique tax-friendly environment for both funds and investors. Attendees can expect to gain valuable insights and knowledge on how to leverage this advantage to drive their business success.
The summit also promises to offer comprehensive training sessions and keynote panels on various topics. These sessions are led by top experts in the field and provide attendees with a wealth of information and insights into the latest trends, strategies, and best practices in the industry.
TC BioPharm management will be presenting on Wednesday, April 26th at 11:00 am ET on Track 2. To schedule a 1X1 meeting with management please email ir@tcbiopharm.com. For more information about the Sequire Investor Summit, including registration details, please visit the official event website at https://puertorico.srax.com/
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue. TC BioPharm uses an allogeneic approach in both unmodified and CAR modified gamma-delta T cells to effectively identify, target and eradicate both liquid and solid tumors in cancer.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company’s proprietary allogenic CryoTC technology to provide frozen product to clinics worldwide. TC BioPharm also maintains a robust pipeline for future indications in solid tumors as well as a significant IP/patent portfolio in the use of CARs with gamma-delta T cells and owns our manufacturing facility to maintain cost and product quality controls.
About SRAX
SRAX Inc. is a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform, Sequire, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visit srax.com and mysequire.com
Contact:
Chris Camarra
EVP Communications
c.camarra@tcbiopharm.com
